Department of Medicine, Nephrology Division, Federal University of São Paulo, São Paulo, SP, Brazil.
Department of Transplantation, Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, SP, Brazil.
PLoS One. 2021 Jul 28;16(7):e0254822. doi: 10.1371/journal.pone.0254822. eCollection 2021.
Kidney transplant (KT) recipients are considered a high-risk group for unfavorable outcomes in the course of coronavirus disease 2019 (COVID-19).
To describe the clinical aspects and outcomes of COVID-19 among KT recipients.
This multicenter cohort study enrolled 1,680 KT recipients diagnosed with COVID-19 between March and November 2020, from 35 Brazilian centers. The main outcome was the 90-day cumulative incidence of death, for the entire cohort and according to acute kidney injury (AKI) and renal replacement therapy (RRT) requirement. Fatality rates were analyzed according to hospitalization, intensive care unit (ICU) admission, and mechanical ventilation (MV) requirement. Multivariable analysis was performed by logistic regression for the probability of hospitalization and death.
The median age of the recipients was 51.3 years, 60.4% were men and 11.4% were Afro-Brazilian. Comorbidities were reported in 1,489 (88.6%), and the interval between transplantation and infection was 5.9 years. The most frequent symptoms were cough (54%), myalgia (40%), dyspnea (37%), and diarrhea (31%), whereas the clinical signs were fever (61%) and hypoxemia (13%). Hospitalization was required in 65.1%, and immunosuppressive drugs adjustments were made in 74.4% of in-hospital patients. ICU admission was required in 34.6% and MV in 24.9%. In the multivariable modeling, the variables related with the probability of hospitalization were age, hypertension, previous cardiovascular disease, recent use of high dose of steroid, and fever, dyspnea, diarrhea, and nausea or vomiting as COVID-19 symptoms. On the other hand, the variables that reduced the probability of hospitalization were time of COVID-19 symptoms, and nasal congestion, headache, arthralgia and anosmia as COVID-19 symptoms. The overall 90-day cumulative incidence of death was 21.0%. The fatality rates were 31.6%, 58.2%, and 75.5% in those who were hospitalized, admitted to the ICU, and required MV, respectively. At the time of infection, 23.2% had AKI and 23.4% required RRT in the follow-up. The cumulative incidence of death was significantly higher among recipients with AKI (36.0% vs. 19.1%, P < 0.0001) and in those who required RRT (70.8% vs. 10.1%, P < 0.0001). The variables related with the probability of death within 90 days after COVID-19 were age, time after transplantation, presence of hypertension, previous cardiovascular disease, use of tacrolimus and mycophenolate, recent use of high dose of steroids, and dyspnea as COVID-19 symptom. On the other hand, the variables that reduced the risk of death were time of symptoms, and headache and anosmia as COVID-19 symptoms.
The patients diagnosed with COVID-19 were long-term KT recipients and most of them had some comorbidities. One in every five patients died, and the rate of death was significantly higher in those with AKI, mainly when RRT was required.
肾移植(KT)受者被认为是在 2019 年冠状病毒病(COVID-19)病程中出现不良结局的高危人群。
描述 COVID-19 在 KT 受者中的临床特征和结局。
这项多中心队列研究纳入了 2020 年 3 月至 11 月期间,来自巴西 35 个中心的 1680 例诊断为 COVID-19 的 KT 受者。主要结局为整个队列和根据急性肾损伤(AKI)和肾脏替代治疗(RRT)需求的 90 天累积死亡率。根据住院、重症监护病房(ICU)入住和机械通气(MV)需求,分析病死率。采用逻辑回归对住院和死亡的概率进行多变量分析。
受者的中位年龄为 51.3 岁,60.4%为男性,11.4%为非裔巴西人。1489 例(88.6%)有合并症,移植后感染的时间为 5.9 年。最常见的症状是咳嗽(54%)、肌痛(40%)、呼吸困难(37%)和腹泻(31%),而临床体征是发热(61%)和低氧血症(13%)。65.1%需要住院治疗,74.4%的住院患者需要调整免疫抑制药物。34.6%需要 ICU 入住,24.9%需要 MV。在多变量建模中,与住院概率相关的变量是年龄、高血压、既往心血管疾病、近期使用大剂量类固醇以及发热、呼吸困难、腹泻和恶心或呕吐等 COVID-19 症状。另一方面,降低住院概率的变量是 COVID-19 症状出现的时间,以及鼻塞、头痛、关节痛和嗅觉丧失等 COVID-19 症状。总的 90 天累积死亡率为 21.0%。住院、入住 ICU 和需要 MV 的患者病死率分别为 31.6%、58.2%和 75.5%。感染时,23.2%有 AKI,23.4%在随访中需要 RRT。AKI 患者(36.0%比 19.1%,P<0.0001)和需要 RRT 的患者(70.8%比 10.1%,P<0.0001)的死亡率显著更高。90 天内死亡的概率与年龄、移植后时间、高血压、既往心血管疾病、使用他克莫司和霉酚酸酯、近期使用大剂量类固醇以及呼吸困难等 COVID-19 症状相关。另一方面,降低死亡风险的变量是症状出现的时间,以及头痛和嗅觉丧失等 COVID-19 症状。
诊断为 COVID-19 的患者是长期 KT 受者,大多数患者有一些合并症。五分之一的患者死亡,AKI 患者的死亡率明显更高,主要是在需要 RRT 时。